In a 69-year-old woman with hyponatremia, is lisinopril or carvedilol (Coreg) more likely responsible, and which angiotensin‑II‑receptor blocker carries the lowest hyponatremia risk?

Lisinopril is more likely responsible for the hyponatremia than carvedilol (Coreg)

ACE inhibitors like lisinopril are well-documented causes of hyponatremia, whereas beta-blockers like carvedilol have minimal association with this electrolyte disturbance. Multiple case reports demonstrate severe symptomatic hyponatremia directly linked to lisinopril therapy 1, 2, with serum sodium normalizing after drug discontinuation. The mechanism involves inappropriate antidiuresis and potential polydipsia secondary to ACE inhibitor therapy 1.

Why Lisinopril is the Culprit

ACE inhibitors cause hyponatremia through modulation of the renin-angiotensin-aldosterone system, leading to altered renal sodium handling and increased antidiuretic hormone activity 3. Guidelines specifically identify hyponatremia (serum sodium <135 mmol/L) as a reason for specialist referral in heart failure patients on ACE inhibitors 4. The 2013 ACC/AHA guidelines emphasize that hyponatremia should be treated with water restriction and "maximization of GDMT that modulate angiotensin II" 3—essentially acknowledging that drugs affecting the renin-angiotensin system contribute to hyponatremia.

Recent evidence confirms this: in heart failure patients, non-use of ARBs was independently associated with hyponatremia in those with normal renal function 5, suggesting that when RAS blockade is absent or suboptimal, hyponatremia risk increases through different mechanisms—but ACE inhibitors themselves can cause it through their specific pharmacologic effects.

Why Carvedilol is Unlikely

The FDA label for Coreg (carvedilol) does not list hyponatremia as a recognized adverse effect 6. The primary concerns with carvedilol are bradycardia (9% in heart failure patients), hypotension (9.7-15.1%), and fluid retention 6. Beta-blockers generally have minimal direct effect on sodium homeostasis. While carvedilol can cause fluid retention requiring diuretic adjustment 6, this represents volume overload rather than dilutional hyponatremia from inappropriate water retention.

Lowest Hyponatremia Risk ARB

For ARB selection with minimal hyponatremia risk, the evidence suggests losartan may be preferable, though all ARBs carry lower hyponatremia risk than ACE inhibitors.

Here's the reasoning:

• Losartan showed no significant difference in adverse renal/electrolyte effects (including hyponatremia risk) between men and women in the HEAAL trial analysis 7
• ARBs as a class appear safer than ACE inhibitors for hyponatremia: Recent data shows ARB use (versus non-use) was protective against hyponatremia in severe CKD patients 5
• Valsartan combined with sacubitril (in ARNI formulation) actually reduces hyperkalemia risk compared to enalapril 8, suggesting favorable electrolyte profile
• Non-use of dihydropyridine calcium channel blockers was independently associated with hyponatremia across all CKD stages 5, suggesting that adding a CCB to ARB therapy may provide additional protection

Practical Algorithm for ARB Selection:

1. First choice: Losartan 25-50 mg daily (best studied for electrolyte safety in heart failure)
2. Alternative: Valsartan 40-80 mg twice daily (especially if considering future ARNI transition)
3. Add amlodipine or other dihydropyridine CCB if additional BP control needed—this combination appears protective against hyponatremia 5
4. Monitor sodium at 1-2 weeks after initiation per guidelines 9, 10, then at 3 months and every 6 months 4

Critical Monitoring Points

When switching from lisinopril to an ARB in this 69-year-old woman:

• Check baseline sodium, potassium, and creatinine before switching
• Recheck at 1-2 weeks post-switch 9, 10—this is when ACE inhibitor/ARB effects on renal function manifest
• Expect sodium to improve once lisinopril is discontinued, as case reports show normalization within days to weeks 1, 2
• Watch for acceptable creatinine rise: up to 0.5 mg/dL increase (or 1.0 mg/dL if baseline >2.0) is tolerable and doesn't require stopping therapy 9
• Avoid potassium-sparing diuretics during ARB initiation 4

The 2018 ACC/AHA hypertension guidelines specifically recommend avoiding thiazide diuretics when hyponatremia is present 11, reinforcing that the ACE inhibitor—not the beta-blocker—is the problem medication here.